What's in Janssen Scientific Affairs, LLC's pipeline?

Janssen Scientific Affairs, LLC has 15 drugs in our index: 6 marketed, 0 filed, 4 in Phase 3, 3 in Phase 2, 2 in Phase 1.

Which companies overlap with Janssen Scientific Affairs, LLC's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Biocad, Azienda Ospedaliera San Giovanni Battista, Basque Health Service.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-scientific-affairs-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Janssen Scientific Affairs, LLC — Portfolio Competitive Intelligence Brief

Janssen Scientific Affairs, LLC pipeline: 6 marketed, 0 filed, 4 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 4 Phase 3 3 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
aspirin (ASA)	aspirin (ASA)	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)	Cardiovascular; Pain management; Immunology
Nucynta ER	Nucynta ER	marketed
TAF/FTC FDC	TAF/FTC FDC	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase	Infectious Disease / Virology
haloperidole	haloperidole	marketed			Other
Darunavir/Cobicistat (FDC)	Darunavir/Cobicistat (FDC)	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease; CYP3A4	Infectious Disease
INI Based Regimen	INI Based Regimen	marketed
Ustekinumab (90 mg)	Ustekinumab (90 mg)	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23	Immunology
Placebo for Ustekinumab	Placebo for Ustekinumab	phase 3
Placebo for Adalimumab	Placebo for Adalimumab	phase 3
Adalimumab (40 mg)	Adalimumab (40 mg)	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)	Immunology

Therapeutic area mix

Immunology · 2
Cardiovascular; Pain management; Immunology · 1
Infectious Disease · 1
Infectious Disease / Virology · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
Biocad · 1 shared drug class
Azienda Ospedaliera San Giovanni Battista · 1 shared drug class
Basque Health Service · 1 shared drug class
Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen Scientific Affairs, LLC:

Cite this brief

Drug Landscape (2026). Janssen Scientific Affairs, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-scientific-affairs-llc. Accessed 2026-05-16.